Ovid Therapeutics Inc. (OVID)
| Market Cap | 467.20M |
| Revenue (ttm) | 7.25M |
| Net Income (ttm) | -17.14M |
| Shares Out | 173.04M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,482,855 |
| Open | 2.690 |
| Previous Close | 2.690 |
| Day's Range | 2.660 - 2.770 |
| 52-Week Range | 0.270 - 3.105 |
| Beta | -0.03 |
| Analysts | Strong Buy |
| Price Target | 4.60 (+70.37%) |
| Earnings Date | May 13, 2026 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d... [Read more]
Financial Performance
In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 70.37% from the latest price.
News
Ovid Therapeutics Transcript: Status update
KCC2 direct activation is a transformative approach for psychotic disorders, with OV4071 showing strong preclinical efficacy and safety. The clinical strategy uses translational biomarkers for rapid proof-of-concept in schizophrenia, Parkinson’s disease psychosis, and Lewy body dementia, backed by broad IP and significant commercial potential.
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.
Ovid Therapeutics Earnings Call Transcript: Q4 2025
Regulatory clearance for OV4071 and strong safety data for OV329 enable pipeline expansion, supported by $60M PIPE financing and potential $53M from warrant exercise, extending cash runway into 2029. Multiple clinical milestones are expected through 2027.
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing OV329, a novel GABA-AT inhibitor, into Phase II for epilepsy with promising safety and efficacy data, while also progressing OV4071, a KCC2 activator, into Phase I for CNS disorders including psychosis. Interim and pivotal data readouts are expected over the next year.
Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a CNS-focused pipeline with differentiated mechanisms, highlighted by OV329 for epilepsy, which shows strong efficacy and tolerability, and OV4071, a KCC2 activator targeting psychosis. Key clinical milestones are expected over the next 6–18 months.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by exces...
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, n...
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, toda...
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT...
Ovid Therapeutics Transcript: Study Result
Phase I results for OV329 in healthy volunteers showed a strong safety profile, no ocular toxicity, and robust GABAergic inhibition exceeding that of vigabatrin. The data support advancing to a phase II-A trial in treatment-resistant focal onset epilepsy, with a 7 mg dose selected for optimal efficacy and safety.
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issue...
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un...
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for ...
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant un...
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP cost...
Ovid Therapeutics Transcript: Status Update
OV329, a next-generation GABA-AT inhibitor, is advancing through a biomarker-rich phase I study with a readout expected in late Q3 2025. Early data show strong safety and target engagement, supporting plans for phase II-A in drug-resistant focal seizures and a differentiated market position.
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, ha...
Ovid Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference
The presentation detailed a differentiated CNS pipeline focused on precision small molecules, highlighting OV329’s progress toward phase II for treatment-resistant epilepsy and the first-in-class KCC2 activators targeting psychosis in Parkinson’s and Lewy body dementia. Key milestones include multiple clinical readouts in 2024–2025 and a strong cash position to support ongoing development.
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move i...
Ovid Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
The presentation detailed a differentiated neurotherapeutics pipeline, highlighting OV329’s promising safety and efficacy profile in epilepsy and the KCC2 platform’s first-in-human milestone for psychosis. Multiple clinical readouts and strong capital position support strategic growth.
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant u...
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today...